Ontology highlight
ABSTRACT: Background
Cefaclor, a second-generation oral cephalosporin, is widely prescribed to treat infectious diseases. Immediate hypersensitivity (HS) reactions to cefaclor have continuously been reported and are expected to increase with its greater use. This study aimed to investigate the clinical characteristics and risk factors of immediate HS to cefaclor over the most recent 5 years.Methods
This retrospective study investigated 521 adverse drug reactions (ADRs) to cefaclor at pharmacovigilance centers at two tertiary hospitals from January 2014 to December 2018. In total, 459 patients with immediate HS to cefaclor were reviewed.Results
A total of 459 cases of cefaclor immediate HS were included among 521 cefaclor ADRs, and anaphylaxis was recorded in 61.2%. Female sex (odds ratio 2.917, 95% confidence interval 2.397-3.550, P?ConclusionsCefaclor was found to elicit high proportions of immediate HS and anaphylaxis. Physicians ought to be cautious with prescribing cefaclor to females, individuals with hypertension, liver diseases, or asthma, and patients taking nonsteroidal anti-inflammatory drugs.Trial registration
This study was retrospectively registered.
SUBMITTER: Rhyou HI
PROVIDER: S-EPMC7885353 | biostudies-literature | 2021 Feb
REPOSITORIES: biostudies-literature
Rhyou Hyo-In HI Doo Go-Eun GE Yoon Jiwon J Ha Chae-Yeon CY Nam Hee-Joo HJ Woo Sung-Dae SD Lee Youngsoo Y Nam Young-Hee YH Ye Young-Min YM
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20210215 1
<h4>Background</h4>Cefaclor, a second-generation oral cephalosporin, is widely prescribed to treat infectious diseases. Immediate hypersensitivity (HS) reactions to cefaclor have continuously been reported and are expected to increase with its greater use. This study aimed to investigate the clinical characteristics and risk factors of immediate HS to cefaclor over the most recent 5 years.<h4>Methods</h4>This retrospective study investigated 521 adverse drug reactions (ADRs) to cefaclor at pharm ...[more]